静脉溶栓治疗在急性轻型非致残性缺血性脑卒中患者中的应用价值

doi:10.3969/j.issn.1671-7171.2025.09.023

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1275 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the application value of intravenous thrombolysis in patients with non-disabling mild acute ischemic stroke.【Methods】 A total of 61 patients with non-disabling mild acute ischemic stroke were divided into an observation group(intravenous thrombolysis combined with dual antiplatelet therapy, n=33) and a control group(dual antiplatelet therapy, n=28) according to different treatment methods. The National Institutes of Health Stroke Scale(NIHSS) scores at 24 h, 72 h, and 7 days after treatment were compared between the two groups. At 3 months after treatment, the modified Rankin Scale(mRS) score, Extended Barthel Index(EBI) score, hematological indices [interleukin-6(IL-6), high-sensitivity C-reactive protein(hs-CRP), and lipoprotein-associated phospholipase A2(Lp-PLA2)], as well as the incidences of symptomatic intracranial hemorrhage, neurological deterioration, and stroke recurrence, were evaluated.【Results】 The NIHSS scores at 24 h, 72 h, and 7 days after treatment in the observation group were significantly lower than those in the control group(P<0.05). After 3 months of treatment, the mRS score, IL-6, and hs-CRP levels in the observation group were lower than those in the control group, while the EBI score and Lp-PLA2 levels were higher than those in the control group(all P<0.05). There were no statistically significant differences in the total incidence of symptomatic intracranial hemorrhage, neurological deterioration, or stroke recurrence between the two groups within 3 months(P>0.05).【Conclusion】 Intravenous thrombolysis can significantly improve early neurological function, promote long-term functional recovery, and reduce systemic inflammatory responses in patients with non-disabling mild acute ischemic stroke, with good safety.

Key words： Stroke Acute Disease Thrombolytic Therapy

Received: 07 May 2025

PACS:

R743.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Donghui
	GAO Ningbo
	SHANG Conghui

Cite this article:

LIU Donghui,GAO Ningbo,SHANG Conghui. Application Value of Intravenous Thrombolysis in Patients with Non-Disabling Mild Acute Ischemic Stroke[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(9): 1569-1571.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.09.023 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I9/1569

[1] 曹亚南,张红,申丹丹. 多元化护理对神经内科介入治疗的脑血管疾病患者心理弹性及生活质量的影响[J].医学临床研究,2024,41(8):1267-1269.
[2] 赵舒平,王雪玲,王文辉. 三七通舒胶囊联合rt-PA静脉溶栓对急性缺血性脑卒中患者IGF-1、MMP-9水平的影响[J].医学临床研究,2023,40(4):543-546.
[3] 邵可可,汝文文,孙冠军. 不同剂量rt-PA静脉溶栓治疗非致残性轻型脑卒中的疗效观察[J].医学美学美容,2020,29(17):22-23.
[4] 姚美芬,丁刚玉,徐建华,等. 急性轻型缺血性脑卒中rt-PA静脉溶栓治疗的疗效分析[J].立体定向和功能性神经外科杂志,2024,37(2):101-106.
[5] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666-682.
[6] KWAH L K, DIONG J. National institutes of health stroke scale(NIHSS)[J].J Physiother,2014,60(1):61.
[7] BRODERICK J P, ADEOYE O, ELM J. Evolution of the modified rankin scale and its use in future stroke trials[J].Stroke,2017,48(7):2007-2012.
[8] 吴炜,倪波业,施加加. 扩展Barthel指数在脑卒中患者中的信度与效度[J].中国康复理论与实践,2021,27(3):261-268.
[9] 王梓晗,储成艳,赵红玲,等. 不同剂量阿替普酶静脉溶栓对急性缺血性脑卒中患者脑血管储备、凝血功能及血清PON-1水平的影响[J].检验医学与临床,2025,22(4):501-505.
[10] 张萌,马咏馨,贾琼,等. 静脉溶栓治疗急性轻型非致残性缺血性脑卒中有效性和安全性的临床观察:一项单中心回顾性观察研究[J].首都医科大学学报,2025,46(1):56-62.
[11] LI S, GU H Q, LI H, et al. Reteplase versus alteplase for acute ischemic stroke[J].N Engl J Med,2024,390(24):2264-2273.
[12] ZHANG F, PENG W X, ZHANG J, et al. PARK7 enhances antioxidative-stress processes of BMSCs via the ERK1/2 pathway[J].J Cell Biochem,2021,122(2):222-234.
[13] 周波. 非心源性缺血性脑卒中静脉溶栓疗效与S100B、NSE、Lp-PLA2及TEG的临床研究[D].合肥:安徽医科大学,2024.
[14] DONG L Y, LI Y M, WU H L. Platelet activating-factor acetylhydrolase II:A member of phospholipase A2 family that hydrolyzes oxidized phospholipids[J].Chem Phys Lipids,2021,239:105103.